Abivax Completes Enrollment for Ulcerative Colitis Phase 3 Trials
Ticker: AAVXF · Form: 6-K · Filed: Apr 29, 2025 · CIK: 1956827
| Field | Detail |
|---|---|
| Company | Abivax S.A. (AAVXF) |
| Form Type | 6-K |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trials, pharmaceuticals, ulcerative-colitis
TL;DR
Abivax enrolled all patients for its Phase 3 UC trials, a big step for their drug obefazimod.
AI Summary
On April 29, 2025, Abivax SA announced the completion of patient enrollment for its Phase 3 ABTECT trials. These trials are investigating the efficacy of obefazimod in patients suffering from moderately to severely active ulcerative colitis.
Why It Matters
This milestone is crucial for Abivax as it moves closer to potential regulatory approval and market entry for its ulcerative colitis treatment, obefazimod.
Risk Assessment
Risk Level: medium — Phase 3 trial results are critical and can significantly impact the company's future, but enrollment completion is a positive step.
Key Players & Entities
- Abivax SA (company) — Registrant
- obefazimod (drug) — Investigational treatment
- April 29, 2025 (date) — Announcement date
FAQ
What is the significance of completing patient enrollment for the ABTECT trials?
Completing enrollment means that the trials can now proceed to the next stages of data collection and analysis, bringing Abivax closer to potential results and regulatory submissions for obefazimod.
What condition are the ABTECT trials investigating?
The ABTECT trials are investigating the treatment of moderately to severely active ulcerative colitis.
What is the name of the drug being tested in the ABTECT trials?
The drug being tested is obefazimod.
When was this announcement made?
The announcement was made on April 29, 2025.
What type of filing is this report?
This report is a Form 6-K, which is a Report of Foreign Private Issuer.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 29, 2025 regarding Abivax S.A. (AAVXF).